Antisense Pharma: Promising Phase IIb Results of Targeted Therapy
with AP 12009 in Recurrent Anaplastic Astrocytoma
CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic
astrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with
AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
REGENSBURG, Germany, May 10th, 2007 - AntisensePharma, a German biopharmaceutical company specialized in targetedtherapies for malignant tumors, today announced, that data from thePhase IIb-study with AP 12009 in high-grade glioma will bepresented at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO), which will be held in Chicago, Illinois,U.S.A, fro...